European Archives - Page 143 of 996 - European Medical Journal

Continue
1 Mins
18 Jul 2024

Gut Dysbiosis Associated with the Severity of Liver Fibrosis Assessed by Magnetic Resonance Elastography

The gut microbiome might affect the severity of metabolic dysfunction-associated steatotic liver disease (MASLD);1⁻3 however, data…
3 Mins
18 Jul 2024

Interview: Mario Strazzabosco

The management of liver cancer has changed dramatically during the 4 decades since I started as an internal medicine speciality fellow…
5 Mins
18 Jul 2024

The Next Frontier in Metabolic Dysfunction-Associated Steatotic Liver Disease

THE FUTURE of metabolic-dysfunction associated liver disease (MASLD) was discussed in an insightful session chaired by Hannes Hagström…
5 Mins
18 Jul 2024

Prevention of Decompensation in Compensated Cirrhosis

Portal hypertension is the major determinant of outcomes in patients with cirrhosis, defined as the presence of a hepatic venous pressure…
4 Mins
18 Jul 2024

Healthy Livers, Healthy Lives

NON-COMMUNICABLE diseases (NCD) represent a major global health challenge, with significant mortality and morbidity. Among these…
2 Mins
18 Jul 2024

Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Interruption in Hepatitis B Virus/HIV Co-Infected Individuals

Among hepatitis B virus (HBV) core antibody positive (cAb+) people with HIV, suppressive HBV treatment, including either tenofovir…
1 Mins
18 Jul 2024

Barriers and Motivators for Implementation of Lifestyle Changes in Metabolic Dysfunction-Associated Steatotic Liver Disease

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) experience difficulties in complying with required lifestyle…
2 Mins
18 Jul 2024

TGR5 Deficiency in Liver Sinusoidal Endothelial Cells Disrupts Angiocrine Signalling After Hepatectomy 

Bile acid (BA) receptors like farnesoid X receptor (FXR) and TGR5 have been implicated in liver regeneration.
7 Mins
18 Jul 2024

EASL 2024 Abstract Highlights

The following highlights spotlight the latest research in hepatology, featuring studies presented at this year’s EASL Congress….

Roche's obesity drug shows promising results at Phase I

Another obesity drug could be on its way to the market after Roche announces positive results for its drug in a phase I trial.